Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who have been diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC) that has a specific gene change (EGFR mutation), confirmed by the enrolling hospital or clinic
• People who have at least one brain tumour (spread from the lung cancer) that can be seen on an MRI brain scan with contrast dye, present before starting targeted drug therapy (TKI)
• People who have not yet started targeted drug therapy (TKI), or who started it no more than 3 months ago, with a recorded start date and scans taken before treatment began
• At the randomisation stage, people who still have brain tumours visible on scans that have not grown or spread, suggesting the tumours are still active but stable

Who may not be able to join:

• People who are unable to have a contrast-enhanced MRI brain scan
• People who have previously had radiation treatment directed at the brain
• People who show signs of cancer spreading along the lining of the brain or spinal cord (leptomeningeal disease), as detected by spine MRI or fluid tests, where these have been performed
• People who have significant neurological symptoms, or who have a brain tumour located in a sensitive area of the brain (such as the brainstem or areas controlling movement) that doctors feel needs immediate radiation treatment
• People who have an active blood cancer, or a second type of solid cancer known to commonly spread to the brain
• People who have had surgery to remove one or more brain tumours, unless at least one additional, untreated brain tumour of visible size remains
• People who, in the investigator's judgement, are unlikely to follow the study procedures and requirements
• Women who are pregnant, breastfeeding, or who could become pregnant — unless highly effective contraception is used throughout the study and for at least 3 months after the last treatment. Men who could father a child must also use highly effective contraception during this time. Highly effective contraception means either two barrier methods, or one barrier method combined with a hormonal method (confirm with trial site for full details)
• At the randomisation stage, people whose brain tumours have clearly progressed in a way that doctors believe requires a change in their main cancer treatment
• At the randomisation stage, people who have brain tumours that a radiation specialist determines cannot safely be treated with a targeted form of radiation called SRS
• At the randomisation stage, people whose brain tumours have completely disappeared on scans
• At the randomisation stage, people who have more than 20 visible brain tumours remaining after initial TKI treatment (note: there is no upper limit on the number of brain tumours at the time of original diagnosis, before treatment begins)

Important: Always verify eligibility with the trial site directly before applying.